Form 4: Rhythm Pharmaceuticals Executive Jennifer Kayden Lee Sells Shares to Cover Tax Obligations

Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, sold 15,515 shares of common stock on March 19, 2024, to cover withholding taxes related to vesting restricted stock units.

Summary

• On March 19, 2024, Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, sold 15,515 shares of common stock.
• The sale was executed at a weighted average price of $39.22 per share, with individual transactions ranging from $39.07 to $39.22.
• The transaction was conducted under a pre-existing Rule 10b5-1 trading plan adopted before February 27, 2023.
• The purpose of the sale was solely to cover withholding taxes associated with the vesting of previously reported restricted stock units.
• Following the reported transaction, Lee directly owns 25,087 shares of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Sales executed under 10b5-1 plans are often pre-scheduled and intended to avoid accusations of insider trading. It is important to note that this sale was to cover tax obligations and may not reflect a change in the executive's confidence in the company.

Key Dates